| 邢相宜,晏子俊,段 磊,于 磊,陈彦清.六味能消胶囊联合复方消化酶对功能性消化不良患者临床症状及脑-肠轴相关因子水平的影响[J].,2021,(9):1702-1705 |
| 六味能消胶囊联合复方消化酶对功能性消化不良患者临床症状及脑-肠轴相关因子水平的影响 |
| Effect of Liuwei Nengxiao Capsule Combined with Compound Digestive Enzyme on Clinical Symptoms and Brain Gut Axis Related Factors in Patients with Functional Dyspepsia |
| 投稿时间：2020-12-07 修订日期：2020-12-30 |
| DOI：10.13241/j.cnki.pmb.2021.09.022 |
| 中文关键词: 六味能消胶囊 复方消化酶 功能性消化不良 脑-肠轴相关因子 临床症状 |
| 英文关键词: Liuweinengxiao capsule Compound digestive enzyme Functional dyspepsia Brain gut axis related factor Clinical symptoms |
| 基金项目:四川省科技厅面上基金项目（2018JY0421）；四川省医学会高血压疾病（施慧达）专项科研课题（2018SHD2-7）；攀枝花市指导性科技计划项目（2019ZD-S-8）；攀枝花市中心医院院内科研课题(201813) |
|
| 摘要点击次数: 992 |
| 全文下载次数: 701 |
| 中文摘要: |
| 摘要 目的：探讨六味能消胶囊联合复方消化酶对功能性消化不良（FD）患者临床症状及脑-肠轴相关因子水平的影响。方法：选取2018年7月~2019年12月期间攀枝花市中心医院收治的80例FD患者，以随机数字表法分为研究组（n=40）和对照组（n=40）。对照组给予复方消化酶治疗，研究组给予复方消化酶联合六味能消胶囊治疗，对比两组的脑-肠轴相关因子水平，疗效，症状改善时间及不良反应。结果：治疗4周后研究组的临床总有效率为92.50%（37/40），高于对照组的72.50%（29/40）（P<0.05）。研究组食量恢复时间（4.62±0.74）d、食欲恢复时间（3.61±0.57）d、恶心呕吐消失时间（1.59±0.36）d分别较对照组的（7.68±1.71）d、（5.71±0.86）d、（3.87±0.52）d缩短（P<0.05）。研究组治疗4周后胃泌素（149.77±13.89）ng/L、胃动素（159.18±12.86）ng/L、神经肽S 受体 1（NPSR1）（164.10±15.88）pg/mL均高于对照组的（93.34±8.92）ng/L、（123.23±10.97）ng/L、（130.23±12.64）pg/mL（P<0.05），研究组治疗4周后降钙素基因相关肽（CGRP）（49.52±6.49）pg/mL、血管活性肠钛（VIP）（22.69±3.61）ng/L、生长抑素（SS）（32.13±3.36）pg/mL低于对照组的（63.19±8.38）pg/mL、（27.83±3.73）ng/L、（41.85±4.38）pg/mL（P<0.05）。两组不良反应发生率对比无明显差异（P>0.05）。结论：复方消化酶联合六味能消胶囊治疗FD患者疗效显著，可有效缓解临床症状，改善脑-肠轴相关因子水平，且不增加不良反应发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Liuwei Nengxiao capsule combined with compound digestive enzyme on clinical symptoms and brain gut axis related factors in patients with functional dyspepsia (FD). Methods: 80 patients with FD who were admitted to Panzhihua Central Hospital from July 2018 to December 2019 were selected, they were randomly divided into study group(n=40) and control group(n=40) according to the digital table method, each group had 40 patients. Patients in the control group were treated with compound digestive enzyme, the study group was treated with compound digestive enzyme combined with Liuweinengxiao Capsule, the levels of brain gut axis related factors, curative effect, clinical symptom improvement time and adverse reactions of the two groups were compared. Results: The total clinical effective rate of study group was 92.50% (37/40), which was higher than 72.50% (29/40) of the control group after 4 weeks of treatment (P<0.05). The recovery time of food intake（4.62±0.74）d, appetite recovery time（3.61±0.57）d, disappearance time of nausea and vomiting（1.59±0.36）d in the study group were respectively shorter than（7.68±1.71）d, （5.71±0.86）d,（3.87±0.52）d of the control group (P<0.05). After 4 weeks of treatment, gastrin (149.77±13.89) ng/L, motilin (159.18 ±12.86) ng/L, neuropeptide S receptor 1(NPSR1) (164.10±15.88) pg/mL in study group were higher than those in control group [(93.34±8.92) ng/L, (123.23±10.97) ng/L, (130.23±12.64) pg/mL](P<0.05). After 4 weeks of treatment, calcitonin gene-related peptide (CGRP) (49.52±6.49) pg/mL, vasoactive intestinal titanium (VIP) (22.69±3.61) ng/L, somatostatin (SS) (32.13±3.36) pg/mL in study group were lower than those in control group (63.19±8.38) pg/mL, (27.83±3.73) ng/L, (41.85±4.38) pg/mL (P<0.05). The incidence of adverse reactions between the two groups was no significant difference(P>0.05). Conclusion: Compound digestive enzyme combined with Liuweinengxiao Capsule treat the patients with FD has remarkable curative effect, which can promote the gastrointestinal motility, effective relief clinical symptoms, which can improve the clinical symptoms and the level of brain gut axis related factors, and it does not increase the incidence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
